Persistence with osteoporosis medications among postmenopausal women in the UK general practice research database

Menopause

Volumn 19, Issue 1, 2012, Pages 33-40

  Li, Lin ^a   Roddam, Andrew ^b   Gitlin, Matthew ^c   Taylor, Andrew ^b   Shepherd, Susan ^b   Shearer, Arran ^b   Jick, Susan ^a  

^a Boston Collaborative Drug Surveillance Program   (United States)

^b AMGEN LTD   (United Kingdom)

^c AMGEN INC   (United States)

Author keywords

Medications; Persistence; Postmenopausal osteoporosis; United Kingdom

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM CARBONATE; ETIDRONIC ACID; IBANDRONIC ACID; RALOXIFENE; RISEDRONIC ACID; STRONTIUM RANELATE;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; DATA BASE; FEMALE; GENERAL PRACTICE; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RESEARCH; MULTIPLE CYCLE TREATMENT; OSTEOPOROSIS; PATIENT COMPLIANCE; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRESCRIPTION; UNITED KINGDOM;

AGED; AGED, 80 AND OVER; ALENDRONATE; BONE DENSITY CONSERVATION AGENTS; DATABASES, FACTUAL; DIPHOSPHONATES; FEMALE; GENERAL PRACTICE; GREAT BRITAIN; HUMANS; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; OSTEOPOROSIS, POSTMENOPAUSAL; PATIENT COMPLIANCE; POSTMENOPAUSE; RALOXIFENE; THIOPHENES; TIME FACTORS;

EID: 84555207362     PISSN: 10723714     EISSN: 15300374     Source Type: Journal    
DOI: 10.1097/gme.0b013e318221bacd     Document Type: Article

References (26)

1. Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 1993;94:646-650.
2. Vasikaran SD. Utility of biochemical markers of bone turnover and bone mineral density in management of osteoporosis. Crit Rev Clin Lab Sci 2008;45:221-258. (Pubitemid 351544135)
3. Gass M, Dawson-Hughes B. Preventing osteoporosis-related fractures: an overview. Am J Med 2006;119:S3-S11.
4. Kanis JA, Burlet N, Cooper C, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2008;19:399-428.
5. Gold DT, McClung B. Approaches to patient education: emphasizing the long-term value of compliance and persistence. Am J Med 2006;119: S32-S37.
6. Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 2006;81:1013-1022. (Pubitemid 44175011)
7. Lo JC, Pressman AR, Omar MA, Ettinger B. Persistence with weekly alendronate therapy among postmenopausal women. Osteoporos Int 2006;17:922-928. (Pubitemid 43781507)
8. Cooper A, Drake J, Brankin E; PERSIST Investigators. Treatment persistence with once-monthly ibandronate and patient support versus onceweekly alendronate: results from the PERSIST study. Int J Clin Pract 2006;60:896-905. (Pubitemid 44082279)
9. Cramer JA, Petak SM, Cziraky M, Barr CE, Poston S. Improved persistence with monthly ibandronate versus weekly bisphosphonates at 9 months. J Clin Densitom 2007;10:S219.
10. Brankin E, Walker M, Lynch N, Aspray T, Lis Y, Cowell W. The impact of dosing frequency on compliance and persistence with bisphosphonates among postmenopausal women in the UK: evidence from three databases. Curr Med Res Opin 2006;22:1249-1256. (Pubitemid 44085576)
11. Gallagher AM, Rietbrock S, Olson M, van Staa TP. Fracture outcomes related to persistence and compliance with oral bisphosphonates. J Bone Miner Res 2008;23:1569-1575.
12. Cotte FE, Mercier F, Pouvourville GD. Relationship between compliance and persistence with osteoporosis medications and fracture risk in primary health care in France: a retrospective case-control analysis. Clin Ther 2008;30:2410-2422.
13. de Lusignan S, van Vlymen J, Hague N, Dhoul N. Using computers to identify non-compliant people at increased risk of osteoporotic fractures in general practice: a cross-sectional study. Osteoporos Int 2006; 17:1808-1814. (Pubitemid 44607402)
14. Cramer JA, Lynch NO, Gaudin AF, Walker M, Cowell W. The effect of dosing frequency on compliance and persistence with bisphosphonate therapy in postmenopausal women: a comparison of studies in the United States, the United Kingdom, and France. Clin Ther 2006; 28:1686-1694. (Pubitemid 44838898)
15. Cramer JA, Gold DT, Silverman SL, Lewiecki EM. A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int 2007;18:1023-1031. (Pubitemid 47019996)
16. Cramer JA, Silverman S. Persistence with bisphosphonate treatment for osteoporosis: finding the root of the problem. Am J Med 2006;119: S12-S17.
17. Imaz I, Zegarra P, González-Enríquez J, Rubio B, Alcazar R, Amate JM. Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis. Osteoporos Int 2010;21:1943-1951.
18. Jick H, Jick SS, Derby LE. Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. BMJ 1991;302:766-768.
19. Jick H, Terris BZ, Derby LE, Jick SS. Further validation of information recorded on a general practitioner based computerized data resource in the United Kingdom. Pharmacoepidemiol Drug Saf 1992; 1:347-349.
20. Jick SS, Kaye JA, Vasilakis-Scaramozza C, et al. Validity of the General Practice Research Database. Pharmacotherapy 2003;23:686-689. (Pubitemid 36539051)
21. García Rodríguez LA, Pérez Gutthann S. Use of the UK General Practice Research Database for pharmacoepidemiology. Br J Clin Pharmacol 1998;45:419-425. (Pubitemid 28227341)
22. Burrell A, Wong P, Ollendorf D, et al. Defining compliance/adherence and persistence: ISPOR Special Interest Working Group. Value Health 2005;8:A194-A195.
23. Peterson AM, Nau DP, Cramer JA, Benner J, Gwadry-Sridhar F, Nichol M. A checklist for medication compliance and persistence studies using retrospective databases. Value Health 2007;10:3-12. (Pubitemid 46161090)
24. Ström O, Landfeldt E, Robbins S, Borgström F. Adherence to treatment of primary osteoporosis and its association to fracture risks - the Swedish Adherence Register Analysis (SARA). Osteoporos Int 2011:doi 10.1007/ s00198-011-1549-6
25. Arden NK, Earl S, Fisher DJ, Cooper C, Carruthers S, Goater M. Persistence with teriparatide in patients with osteoporosis: the UK experience. Osteoporos Int 2006;17:1626-1629. (Pubitemid 44477622)
26. Sikka R, Xia F, Aubert RE. Estimating medication persistency using administrative claims data. Am J Manag Care 2005;11:449-457. (Pubitemid 41022729)